Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT04355676
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 190
- Registration Number
- NCT04349098
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
- Conditions
- Colorectal Cancer (CRC)Non-Small Cell Lung Carcinoma (NSCLC)Other Solid Tumors
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 126
- Registration Number
- NCT04256707
- Locations
- 🇮🇱
Hadassah Ein Karem University Hospital, Jerusalem, Israel
🇮🇱University Hospital Assuta Ashdod, Ashdod, Israel
🇮🇱Soroka University Medical Center, Beer-Sheva, Israel
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
- Conditions
- Endometrial Cancer
- Interventions
- Drug: Matching placebo for selinexor
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 263
- Registration Number
- NCT03555422
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇨🇦London Health Sciences Centre (London Regional Cancer Centre), London, Ontario, Canada
🇺🇸Oncology Associates of Oregon, Eugene, Oregon, United States
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 402
- Registration Number
- NCT03110562
- Locations
- 🇨🇦
Princess Margaret Cancer Research, Toronto, Ontario, Canada
🇺🇸Kaiser Permanente Hawaii, Honolulu, Hawaii, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 60
- Registration Number
- NCT02702492
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCLA Health, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Higher-Risk Myelodysplastic Syndrome (HR-MDS)Newly Diagnosed Intermediate/High-Risk MDSAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 277
- Registration Number
- NCT02649790
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center Clinical Research Unit, Philadelphia, Pennsylvania, United States
🇺🇸(USO) Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Ohio State University, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02628704
- Locations
- 🇺🇸
James R. Berenson MD, Inc, West Hollywood, California, United States
🇺🇸Waverly Hematology, Cary, North Carolina, United States
Selinexor in Advanced Liposarcoma
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 342
- Registration Number
- NCT02606461
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 33
- Registration Number
- NCT02431364
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia